SOUTH AFRICAN HYPERTENSION GUIDELINE 2011

1. INTRODUCTION

2. OBJECTIVE AND METHODOLOGY

3. MEASUREMENT OF BP
   3.1 Generic measurement principles
   3.2 Mercury sphygmomanometer
   3.3 Self- and ambulatory BP monitoring

4. CARDIOVASCULAR DISEASE RISK STRATIFICATION
   4.1 Rationale for cardiovascular risk assessment
   4.2 Risk factors, TOD and ACC
   4.3 Routine baseline investigations

5. GOALS OF BP-LOWERING TREATMENT

6. SUSTAINABLE HYPERTENSION MANAGEMENT AND SCARCE RESOURCES

7. MANAGEMENT
   7.1 Lifestyle modification
   7.2 Drug therapy
      7.2.1 Consensus statement on the use of ACE-Is and ARBs
      7.2.2 Compelling indications for a specific drug class
      7.2.3 Direct renin inhibitor
      7.2.4 New trials
      7.2.5 Combination treatment in hypertension
   7.3 Fixed drug combinations in hypertension and hyperlipidaemia
   7.4 Antihypertensive drug interactions

8. MANAGEMENT OF SEVERE HYPERTENSION
   8.1 Asymptomatic severe hypertension
   8.2 Hypertensive urgencies and emergencies
      8.2.1 Hypertensive urgency
      8.2.2 Hypertensive emergency
         8.2.2.1 Acute cerebrovascular syndromes
         8.2.2.2 Acute cardiac syndromes
         8.2.2.3 Postoperative hypertension

9. SPECIAL CONSIDERATIONS FOR HYPERTENSION IN CERTAIN POPULATIONS
   9.1 Hypertension in blacks and Asians
   9.2 Hypertension in children and adolescents
   9.3 Hypertension in pregnancy
      9.3.1 Treatment
      9.3.2 Hypertensive emergencies (impending eclampsia, eclampsia)
   9.4 Hypertension in persons living with HIV/AIDS
   9.5 Control of hypertension with diabetes

10. PRIMORDIAL PREVENTION

11. PREVENTION OF HYPERTENSION

12. PATIENT EDUCATION

13. ONGOING MANAGEMENT OF THE PATIENT WITH HYPERTENSION
CONTENTS

14. STRATEGIC IMPLICATIONS FOR IMPLEMENTING THIS GUIDELINE
15. DISCLAIMER
REFERENCES
Annexure A: Abbreviations
Annexure B: Checklist for therapeutic patient education
Annexure C: Strategic implications for the implementation of this guideline
Table I. Different methods of BP measurement
Table II. Stratification of risk to quantify prognosis
Table III. Major risk factors, target organ damage (TOD) and associated clinical conditions (ACC)
Table IV. International Diabetes Federation (IDF) definition of diabetes
Table V. Routine investigations
Table VI. Goals of BP-lowering treatment
Table VII. Lifestyle modification for hypertension care
Table VIII. Indications and contraindications for the major classes of antihypertensive drugs
Table IX. Current South African norms for dyslipidaemia, obesity and diabetes
Table X. Interactions between antihypertensives and other drugs
Table XI. Intravenous and oral drugs for hypertensive emergency
Table XII. Causes of resistant hypertension in South Africa
Table XIII. 95th percentile of BP in boys and girls aged 3 - 16 years, according to height
Table XIV. Obstacles to adherence
Fig. 1. Southern African hypertension management flow diagram based on added CVD risk

© 2011 Southern African Hypertension Society